Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin versus linezolid for community-acquired bacterial pneumonia
2014-002683-32Phase 3Terminated
- Sponsor
- Durata Therapeutics
- Start
- Feb 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in community acquired pneumonia (CAP) comparing Dalbavancin arm with Linezolid comparator arm (2 arms). Started Feb 2015; status: terminated.
02
Drugs
dalbavancinlinezolid
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2014-002683-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002683-32.